Diovan |
Valsartan is an angiotensin II receptor antagonist, acting on the AT1 subtype. In
the U.S., valsartan is indicated for treatment of high blood pressure, of congestive
heart failure (CHF), and post-myocardial infarction (MI). It is marketed
by Novartis under the trade name Diovan®. In India, it is marketed by CIPLA under
the trade name Valtan. In 2005, Diovan® was prescribed more than 12 million
times in the United States. A study released by the Journal of Clinical Investigation
in 2007 found some efficacy in the use of Valsartan in the treatment and
prevention of Alzheimer's Disease although such use is considered to be highly
experimental.[1] Administration Oral tablets, containing 40 mg (scored), 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40–320 mg daily. In some markets available as a Hard Gelatin Capsule, containing 40mg, 80mg, or 160mg of valsartan. Diovan HCT® contains a combination of Valsartan and hydrochlorothiazide but, unlike Diovan®, is only indicated for hypertension, not for CHF or post-MI. Myocardial infarction A recent meta-analysis published in the peer-reviewed journal Circulation demonstrated that angiotensin II receptor antagonist induce myocardial infarction compared to placebo.[2] Side effects Most commonly, headache and dizziness. |